RxDoctor Payments Data

Kris Scalf

Women's Health · Saint Louis, MONPI 1376750109

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 367 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Among women's health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,540in general payments, 2019–2025

Across 367 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Mayne Pharma Commercial LLC$729
  • Evofem Biosciences, Inc.$679
  • Coopersurgical, Inc.$422
  • Millicent US Inc$400
  • Amgen$383
  • plus $3K from 31 others

What the payments were for

  • Food & beverage$6,36297%
  • Education$1783%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,540 in reported general payments places this provider in the 95th percentile of 208 women's health providers in Missouri.

See all women's health providers in Missouri

Medicare billing

Part B allowed, 2024
$14,013
Medicare patients
77
Services billed
408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol42$4,005
PremarinEstrogens, Conjugated13$2,820
ValacyclovirValacyclovir Hcl18$951
Ibandronate Sodium14$520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$86$2,82013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 208 women's health providers in Missouri.

Other women's health in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →